Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Licitra

Showing results (81-90 of 311) with videos related to

Pageof 32
Sort By:
Frontiers in Oncology|February 11, 2020
Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based TherapySandro V Porceddu, Florian Scotté, Matti Aapro, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 3, 2024
Comprehensive insights on the underlying potential and advantage of proton therapy over intensity-modulated photon radiation therapy as highlighted in a wide real world data analysisEster Orlandi, Giulia Fontana, Lisa Licitra, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 17, 2018
Use of apparent diffusion coefficient images to predict response to induction chemotherapy in sinonasal cancerMarco Bologna, Eros Montin, Valentina D A Corino, et al.
Cancer Chemotherapy and Pharmacology|April 10, 2014
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neckVassiliki Saloura, Ezra E W Cohen, Lisa Licitra, et al.
Tumori|May 18, 2004
Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapyMauro Palazzi, Marco Guzzo, Paolo Bossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinomaFederica Perrone, Paolo Bossi, Barbara Cortelazzi, et al.
Oral Oncology|June 22, 2022
NR4A3 fusion molecular profile change pathological diagnosis? A case reportIlaria Pellegrini, Pasquale Quattrone, Gianpaolo Dagrada, et al.
Frontiers in Oncology|January 5, 2026
LAT1 expression in head and neck cancer: a prognostic biomarker with potential relevance for BNCTStefano Cavalieri, Imperia Nuzzolese, Deborah Lenoci, et al.
Oral Oncology|July 18, 2016
Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancerLisa Licitra, Ulrich Keilholz, Makoto Tahara, et al.
Advances in Oto-Rhino-Laryngology|July 31, 2020
Treatment Options for Recurrent Anterior Skull Base TumorsEster Orlandi, Nicola Alessandro Iacovelli, Rossana Ingargiola, et al.
Pageof 32

Showing results (81-90 of 311) with videos related to

Sort By:
Pageof 32
Frontiers in Oncology|February 11, 2020
Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based TherapySandro V Porceddu, Florian Scotté, Matti Aapro, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 3, 2024
Comprehensive insights on the underlying potential and advantage of proton therapy over intensity-modulated photon radiation therapy as highlighted in a wide real world data analysisEster Orlandi, Giulia Fontana, Lisa Licitra, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 17, 2018
Use of apparent diffusion coefficient images to predict response to induction chemotherapy in sinonasal cancerMarco Bologna, Eros Montin, Valentina D A Corino, et al.
Cancer Chemotherapy and Pharmacology|April 10, 2014
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neckVassiliki Saloura, Ezra E W Cohen, Lisa Licitra, et al.
Tumori|May 18, 2004
Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapyMauro Palazzi, Marco Guzzo, Paolo Bossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinomaFederica Perrone, Paolo Bossi, Barbara Cortelazzi, et al.
Oral Oncology|June 22, 2022
NR4A3 fusion molecular profile change pathological diagnosis? A case reportIlaria Pellegrini, Pasquale Quattrone, Gianpaolo Dagrada, et al.
Frontiers in Oncology|January 5, 2026
LAT1 expression in head and neck cancer: a prognostic biomarker with potential relevance for BNCTStefano Cavalieri, Imperia Nuzzolese, Deborah Lenoci, et al.
Oral Oncology|July 18, 2016
Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancerLisa Licitra, Ulrich Keilholz, Makoto Tahara, et al.
Advances in Oto-Rhino-Laryngology|July 31, 2020
Treatment Options for Recurrent Anterior Skull Base TumorsEster Orlandi, Nicola Alessandro Iacovelli, Rossana Ingargiola, et al.
Pageof 32